<DOC>
	<DOCNO>NCT00381940</DOCNO>
	<brief_summary>This phase II trial study side effect efficacy bortezomib ifosfamide vinorelbine child young adult Hodgkin 's lymphoma recurrent respond previous therapy . Bortezomib inhibitor protein degradation . Bortezomib degrade short-lived regulatory protein cell , report increase tumor cell . Bortezomib may increase effectiveness ifosfamide vinorelbine ( two standard drug give child Hodgkin Lymphoma come back initial treatment ) make cancer cell sensitive effectiveness standard chemotherapy prevent anti-death response drug . Giving bortezomib together ifosfamide vinorelbine tartrate kill cancer cell kill ifosfamide vinorelbine alone .</brief_summary>
	<brief_title>Bortezomib , Ifosfamide , Vinorelbine Tartrate Treating Young Patients With Hodgkin 's Lymphoma That Recurrent Did Not Respond Previous Therapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine efficacy safety bortezomib ( chemosensitizing agent ) pediatric patient young adult primary refractory Hodgkin 's lymphoma ( HL ) HL first relapse . II . Determine response rate patient treat bortezomib , ifosfamide , vinorelbine ditartrate ( vinorelbine tartrate ) ( IVB ) compare response rate historical response rate patient treat ifosfamide vinorelbine ditartrate alone . SECONDARY OBJECTIVES : I . Determine overall response rate ( complete partial response ) induction success rate 2 4 course therapy reinduction rate ( complete response ) 4 course therapy . II . Determine proportion patient able mobilize sufficient hematopoietic stem cell ( CD34+ ) 2 course IVB . OUTLINE : This multicenter , open-label , pilot study . Patients receive ifosfamide intravenously ( IV ) continuously day 1-4 , vinorelbine tartrate IV 6-10 minute day 1 5 , bortezomib intravenously day 1 , 4 , 8 , filgrastim ( G-CSF ) vein subcutaneously begin day 6 continue blood count recover peripheral blood stem cell ( PBSC ) harvest . Treatment cycle repeat every 21 day 2 4 course absence disease progression unacceptable toxicity . Patients undergo autologous PBSC harvest accord institutional guideline second course therapy . After completion study treatment , patient follow every 6 month 2 year annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm Hodgkin 's lymphoma time relapse disease progression , meet follow criterion : Stage IIV disease No morphologically unclassifiable disease Meets 1 follow criterion : Mixed cellularity Lymphocytic depletion ( LD ) LD , diffuse fibrosis LD , reticular Lymphocyte predominance ( LP ) LP , diffuse LP , nodular Nodular sclerosis ( NS ) NS , cellular phase NS , lymphocytic predominance NS , mixed cellularity NS , LD Not otherwise specify Primary refractory disease OR disease first relapse , except follow : Patients achieve complete response treatment protocol COGAHOD0431 experience biopsyproven recurrence doxorubicin hydrochloride , vincristine , prednisone , cyclophosphamide without involvedfield radiotherapy Patients observationonly arm protocol COGAHOD0431 Any measurable , focal mass lesion visceral organ ( e.g. , liver , spleen , kidney ) Patients metastatic disease bone marrow granulocytopenia , anemia , and/or thrombocytopenia allow provide follow criterion meet : Platelet count ≥ 20,000/mm³ ( platelet transfusion allow ) Hemoglobin ≥ 8 g/dL ( pack red blood cell transfusion allow ) Karnofsky performance status ( PS ) 60100 % ( patient &gt; 16 year age ) OR Lanksy PS 60100 % ( patient = &lt; 16 year age ) Life expectancy &gt; = 2 month Absolute neutrophil count &gt; = 1,000/mm^3 Platelet count &gt; = 75,000/mm^3 ( transfusion independent ) ( patient bone marrow involvement ) Creatinine = &lt; 1.5 time upper limit normal ( ULN ) Creatinine clearance radioisotope glomerular filtration rate &gt; = 70 mL/min/1.73 m^2 AST ALT = &lt; 2.5 time ULN Bilirubin = &lt; 1.5 time ULN Shortening fraction &gt; = 27 % echocardiogram OR LVEF &gt; = 50 % gate radionuclide study Patients seizure disorder eligible nonenzymeinducing anticonvulsant seizures well control No CNS toxicity &gt; grade 2 No serious intercurrent illnesses No known hypersensitivity E. coliderived protein , filgrastim ( GCSF ) , component study drug No peripheral neuropathy &gt; grade 1 No know hypersensitivity bortezomib , boron , mannitol No concurrent chemotherapy immunomodulating agent ( include steroid ) Concurrent corticosteroid allow treatment prophylaxis anaphylactic reaction No dexamethasone aprepitant antiemetic Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Recovered prior therapy No prior bortezomib proteasome inhibitor At least 3 week since prior chemotherapy ( 4 week nitrosoureas ) More 14 day since prior investigational drug No concurrent enzyme induce anticonvulsant alter p450 metabolism , include phenytoin , carbamazepine , phenobarbital , anticonvulsant Benzodiazepine gabapentin allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>